Invivyd launches discovery program for measles monoclonal antibody; candidate target by 2025

Invivyd, Inc.

Multiple healthcare providers have requested a monoclonal antibody for measles treatment and post-exposure prophylaxis from Invivyd.
Goal is to identify a preclinical measles mAb candidate in 2025; progress update expected by end of year.
Over 20 million Americans are unvaccinated; U.S. at risk of losing functional elimination as vaccination rates decline.
No approved therapies currently exist for measles; current options include high-dose Vitamin A and IVIG, both with limitations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.